

DOCKET NO.: 093/USTPCT2008 0055-191082

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Barry A. Morgan et al.

Application No.: 09/980,943

Group Art Unit: 1615

X

Filed:

February 22, 2002

Examiner:

Unknown

Title:

CYCLIC PEPTIDES TO SOMATOSTATIN AGONISTS

## **CERTIFICATE OF MAILING**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit:

Alan F. Feeney

## INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

	ant Commissioner for Patents ngton, D.C. 20231
	iformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)
[ ]	under 37 CFR 1.97(c) together with either:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[ ] a \$240.00 fee under 37 CFR 1.17(p), or  (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a Petition under 37 CFR 1.97(d)(2), and
	[ ] a \$130.00 petition fee set forth in 37 CFR 1.17(i).  (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)
[ ]	Applicant requests that the attached IDS and cited reference(s) [ ] be placed in the application filewrapper. (Filed after payment of issue fee)
[ X ]	The listed references were cited in the enclosed Search Report which issued in connection with the corresponding

## Statement Under 37 CFR 1.97(e)

[]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
[ X ]	Enclosed herewith is form PTO-1449, with copies of the references noted thereon; with a Certificate of Mailing.
[]	Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [ ], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).
Concise	Explanation Requirement (non-English references):
[]	The "concise explanation" requirement for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
	[ ] the explanation provided on the attached sheet.
	[ ] the explanation provided in the Specification.
	[ ] submission of the enclosed International Search Report.
	[ ] the enclosed English language abstracts.
enclose	uested that the information disclosed herein be made of record in this application, and that the references listed on the d form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, 1302.12).
Method	of payment:
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
[X ]	No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
[X]	The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.
Dated:	Respectfully submitted, BIOMEASURE, INCORPORATED  By  Alan F. Feeney, Attorney for Applicant(s)  Registration No.: 43,609  Telephone: (508) 478-0144  Facsimile: (508) 473-3531

27 Maple Street Milford, Massachusetts 01757